Key result
Treatment with bevacizumab and nab-paclitaxel led to disease stabilization without new metastatic lesions after 6 months in a patient with metastatic epithelioid hemangioendothelioma.
Why the study?
Does bevacizumab and nanoparticle albumin-bound paclitaxel improve stabilization of disease in a patient with metastatic epithelioid hemangioendothelioma?
Case Report (n=1)
No
Does bevacizumab and nanoparticle albumin-bound paclitaxel improve stabilization of disease in a patient with metastatic epithelioid hemangioendothelioma?
This is the first case report describing the activity of the combination of chemotherapy and bevacizumab in epithelioid hemangioendothelioma, showing disease stabilization.
Supports further study of bevacizumab plus nab-paclitaxel; single case leaves efficacy unproven.
This report describes a patient with metastatic epithelioid hemangioendothelioma treated with bevacizumab and nanoparticle albumin-bound paclitaxel. The treatment was well tolerated and led to the stabilization of an aggressive variant of the disease. This case report is the first one that describes the activity of the combination of chemotherapy and bevacizumab in epithelioid hemangioendothelioma. Literature describing the activity of bevacizumab and other agents (thalidomide, lenalidomide, and interferon) believed to possess anti-angiogenic activities is also reviewed.
No takes yet. Share an insight, caveat, or question.
Gaur et al. (2012) conducted a case report in Metastatic epithelioid hemangioendothelioma (n=1). Bevacizumab and nab-paclitaxel was evaluated on Disease response. Treatment with bevacizumab and nab-paclitaxel led to disease stabilization without new metastatic lesions after 6 months in a patient with metastatic epithelioid hemangioendothelioma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: